Two Point Capital Management Inc. Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Two Point Capital Management Inc. acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, HoldingsChannel.com reports. The fund acquired 10,218 shares of the medical research company’s stock, valued at approximately $4,143,000. Thermo Fisher Scientific comprises 1.8% of Two Point Capital Management Inc.’s investment portfolio, making the stock its 22nd biggest position.

Several other hedge funds have also bought and sold shares of TMO. Ameritas Advisory Services LLC raised its stake in shares of Thermo Fisher Scientific by 5.1% in the second quarter. Ameritas Advisory Services LLC now owns 3,991 shares of the medical research company’s stock worth $1,618,000 after buying an additional 195 shares during the period. HighMark Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 140.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after buying an additional 45 shares in the last quarter. Synergy Asset Management LLC purchased a new position in shares of Thermo Fisher Scientific in the second quarter worth $1,425,000. Hilltop National Bank bought a new position in shares of Thermo Fisher Scientific during the second quarter worth $339,000. Finally, Mechanics Financial Corp increased its holdings in Thermo Fisher Scientific by 53.9% in the 2nd quarter. Mechanics Financial Corp now owns 3,148 shares of the medical research company’s stock valued at $1,276,000 after acquiring an additional 1,102 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock opened at $525.07 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $611.49. The stock has a market cap of $198.27 billion, a PE ratio of 30.37, a P/E/G ratio of 2.88 and a beta of 0.77. The company has a 50-day moving average price of $481.27 and a 200 day moving average price of $447.60.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 in the last ninety days. 0.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research analyst reports. Barclays raised their price objective on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research report on Thursday. Robert W. Baird raised their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Finally, HSBC reissued a “hold” rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $585.37.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.